Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
03 avr. 2024 08h40 HE
|
Surrozen, Inc.
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
27 nov. 2023 08h35 HE
|
GRI Bio, Inc.
Clinical development plan leveraging 505(b)(2) regulatory pathway Initiation of Phase 2a biomarker study on track to start before year end Currently available treatments for IPF are limited to...
Idiopathic Pulmonary Fibrosis Market to Show Immense Growth at a CAGR of 6.6% During the Study Period (2019–2032) | DelveInsight
30 oct. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Idiopathic Pulmonary Fibrosis Market to Show Immense Growth at a CAGR of 6.6% During the Study Period (2019–2032) | DelveInsight The overall...
GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference
19 oct. 2023 08h45 HE
|
GRI Bio, Inc.
Findings demonstrate that the number of NKT cells positively correlates with the number of airway macrophages in IPF patients GRI Bio on track to launch Phase 2a biomarker...
Kinarus Therapeutics Announces Personnel Change
12 juil. 2023 01h00 HE
|
Kinarus Therapeutic Holding AG
Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and...
Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting
29 juin 2023 12h00 HE
|
Kinarus Therapeutic Holding AG
Basel, Switzerland, 29 June 2023. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral,...
GRI Bio (NASDAQ: GRI) Bolsters Patent Portfolio
27 juin 2023 08h45 HE
|
GRI Bio, Inc.
- U.S. patent issuance for lead program, GRI-0621, in development for the treatment of idiopathic pulmonary fibrosis (IPF) - Company building a robust global patent estate LA JOLLA, CA, June...
Ocean Biomedical, Inc. Joins the Russell 2000® Index
27 juin 2023 08h01 HE
|
Ocean Biomedical, Inc.
Ocean Biomedical’s Inclusion in the Russell 2000® Index and Russell 3000® Index Builds Momentum for Cutting Edge Therapeutic Programs Targeting Multiple Cancers, Fibrotic Diseases, and Malaria ...
Kinarus Therapeutics signed subordinated bridge loans to ensure further liquidity
27 juin 2023 01h00 HE
|
Kinarus Therapeutic Holding AG
Basel, Switzerland, June 26, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and...
Avalyn Pharma Highlighting Inhalation Platform at Upcoming H.C. Wainwright and Hanson Wade Conferences in June
15 juin 2023 08h00 HE
|
Avalyn Pharma Inc.
SEATTLE, June 15, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases,...